Sanofi Seen Making Formal Genzyme Bid
PARIS (TheStreet) -- Sanofi-Aventis(SNY) CEO Chris Viehbacher has support from the board to offer as much as $70 a share for Genzyme(GENZ), or about $18.7 billion, Bloomberg reports.
Sanofi, France's largest drugmaker, is preparing a formal approach, and plans to send a letter to Genzyme in a few days that will detail its interest and give a specific price, said three people with knowledge of the situation, Bloomberg reports. The CEO declined to comment on Genzyme in a conference call with reporters Wednesday. "We can't comment on specific speculation," he said, after announcing that Sanofi earnings rose 61% in the second quarter. Genzyme, the world's largest maker of medicines for genetic diseases, last week rebuffed an informal approach by Sanofi to enter talks, said people familiar with the situation, according to Bloomberg. Genzyme shares closed Wednesday at $68. -- Written by Joseph Woelfel in New York. Get more stock ideas and investing advice on our sister site, Stockpickr.com.>To order reprints of this article, click here: ReprintsTheStreet Premium Services For Personal Service: 877-471-2967
Jim Cramer's Action Alerts PLUS:
Trade right alongside a Wall Street pro — enjoy access to his Charitable Trust portfolio and be sent trade alerts BEFORE he makes a move. Learn More
ETF Profits:
Get money-making ideas from the hottest investment vehicle on the planet. Our experts show you how to play various ETF sectors to help pump-up your portfolio. Learn More
OptionsProfits:
Get 50+ trade ideas a week from the industry's top options experts. Plus — exclusive commentary on market trends and essential trading tools. Learn More
Real Money:
Our team of professional Wall Street Pros — including Jim Cramer, Doug Kass, and Nicholas Vardy — delivers intelligent analysis, timely trade ideas, and colorful commentary. Learn More
Stocks Under $10:
Break into the market with small- and mid-cap stocks... all $10 or less! David Peltier tells you exactly which low-priced stocks he's buying and selling. Learn MoreTo begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
blog comments powered by Disqus
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 12,845.13 | 1,344.33 | 2,901.99 | 19.01 |
Oil *
116.38
|
|
DOWN
17.10 |
DOWN
0.57 |
DOWN
3.67 |
DOWN
0.48 |
10 Yr
1.90%
SPDR Gold
167.64
|
|
-0.13%
|
-0.04%
|
-0.13%
|
-2.46%
|
Data delayed 20 minutes |
Connect with TheStreet